Exhibit 10.1
*** Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 CFR §§240.24b-2
2013 Corporate Goals for Strategic Leadership Team
Approved by the Compensation Committee on April 29, 2013
Revenue and Operating Income (50)%
Revenues for the Year - 20%
Interpolation will be used.
|
| | | |
| Total Revenue Growth Vs. Prior Year | | Funding | *Corresponding Unit Growth Rate |
| ≥ [***]% growth | | 200% | [***] |
| ≥ [***]% growth | | 175% | [***] |
| ≥ [***]% growth | | 150% | [***] |
| ≥ [***]% ([***]) | | 125% | [***] |
| ≥ [***]% growth | | 100% | [***] |
| ≥ [***]% growth | | 75% | [***] |
| ≥ [***]% growth | | 50% | [***] |
| ≥ [***]% growth | | 25% | [***] |
| < [***]% growth | | No Payout | |
* reference only not calculated in the funding
Q4 Revenue Implications - 20%
Interpolation will be used.
• Q4 2013 growth over Q4 2012 - $13.6 million
|
| | | |
| Q4 Total Revenue Growth Vs. Prior Year | | Funding | Q4 Revenues |
| ≥ [***]% growth | | 200% | [***] |
| ≥ [***]% growth | | 175% | [***] |
| ≥ [***]% growth | | 150% | [***] |
| ≥ [***]% growth | | 125% | [***] |
| ≥ [***]% growth | | 100% | [***] |
| ≥ [***]% growth | | 75% | [***] |
| < [***]% growth | | No Payout | |
Operating Income (millions) - 10%
Interpolation will be used.
|
| | | |
| Operating Income (Loss) [***] | | Operating Loss +/- | Funding |
| ([***]) | | 60% | 200% |
| ([***]) | | 70% | 175% |
| ([***]) | | 80% | 150% |
| ([***]) | | 90% | 125% |
| ([***]) target [***] | | 100% | 100% |
| ([***]) | | 110% | 75% |
| ([***]) | | 120% | 50% |
| ([***]) | | 130% | 25% |
| ([***]) | | 140% | No Payout |
Managed Care (30%)
• 2 Commercial Plans (> [***] million lives in total) - 20%
○ +5% payout for each additional plan having > [***] million lives
○ e.g., 3 plans = 25% payout
• 8 Employer Conversions (> [***] lives each) - 5%
• 1 Major National Plan Win (or very high likelihood of coverage in the new year) - 5%
○ +5% if delivered by end of [***] (e.g., 10% payout)
○ +10% if delivered by end of [***] (e.g., 15% payout)
HDL-P (10%)
• FDA Clearance by the end of Q4
Compliance & Ethics (10%)
• 5% - meet the timely completion requirements of Sunshine Act
• 5% - no significant deficiency re: Adva Med Policy
[***] Certain confidential information in this document, marked by bracketed asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions.
